Latest Breaking News On - Chronic communications inc - Page 14 : comparemela.com

Hancock Jaffe Laboratories, Inc.: First U.S. Patent Allowed on Hancock Jaffe VenoValve IRVINE, CA / ACCESSWIRE / February 24, 2021 / Hancock Jaffe Laboratories, Inc. (NASDAQ:HJLI), a developer of medical devices that restore cardiac and vascular health, today announced that it has received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a patent covering the company s VenoValve. The patent, which focuses on novel aspects of the VenoValve frame, will be the first to issue among several VenoValve patent applications pending in the U.S. and throughout the world. The VenoValve is a clinical stage device that is being developed to treat a debilitating condition known as chronic venous insufficiency (CVI) of the deep venous system. CVI occurs when valves inside the veins of the leg fail, causing blood to flow in the wrong direction (reflux), and increasing venous pressure (venous hypertension). This results in leg swelling, pain, open sores (venou

United statesMichelle mcadamHancock jaffeRobert bermanExchange commissionTrademark officeHancock jaffe laboratories incDrug administrationChronic communications incCompany receives notice of allowanceCompany receives noticeHancock jaffe laboratoriesUnited states patentJaffe laboratoriesChronic venous insufficiencyPrivate securities litigation reform act